← 홈

전체 프로그램

ADC 1032 · Antibody 4684 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 31일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,531개
AntibodystaleInstitut du Cancer de Montpelli…Phase 2

trastuzumab (Herceptin, Gemcitabine - Trastuzumab - Erlotinib)

Metastatic Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma

#MetastaticPancreaticAdenocarcino#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSeoul National University Hospi…Phase 2

nivolumab (Opdivo, Gemcitabine+ nivolumab)

Recurrent or Metastatic Nasopharyngeal Carcinom · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#Antibody#Phase2#항체#면역항체+2
효능 ORR 69.6%임상시험 1상태 ACTIVE
AntibodystaleRoswell Park Cancer InstitutePhase 2

Gemcitabine, Capecitabine and Bevacizumab (Gemcitabine, Capecitabine and Bevacizumab)

Cholangiocarcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, Gemcitabine/Cisplatin/Nivolumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 ACTIVE
ADCBiologicstaleChangchun GeneScience Pharmaceu…Phase 1

GenSci139 (GenSci139)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstaleInstitut National de la Santé E…Phase 1

Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes (Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleNanoscope Therapeutics Inc.Phase 2

Gene Therapy-vMCO-010 (Gene Therapy-vMCO-010)

Stargardt Disease · Stargardt Disease

#StargardtDisease#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTAAVBiologicstaleTippi MackenziePhase 1

Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase (Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase)

GM1 Gangliosidoses; GM1 Gangliosidosis, Type I · GM1 Gangliosidoses

#GM1Gangliosidoses#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodyBiologicstaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleGuangzhou JOYO Pharma Co., LtdPhase 1

Second dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2
효능 ORR 38%임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）)

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleGenSight BiologicsPhase 2

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

Non-syndromic Retinitis Pigmentosa · Non-syndromic Retinitis Pigmentosa

#Non-syndromicRetinitisPigmentosa#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleChildren's Hospital Medical Cen…Phase 2

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Hereditary Pulmonary Alveolar Proteinosis · Hereditary Pulmonary Alveolar Proteinosi

#HereditaryPulmonaryAlveolarProte#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleMuscular Dystrophy AssociationPhase 1

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
CGTBiologicstaleAdaptimmunePreclinical

Genetically engineered T Cell Receptors (Genetically engineered T Cell Receptors)

Solid and Hematological Malignancies · Solid and Hematological Malignancies

#SolidandHematologicalMalignancie#CGT#Preclinical#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED

118 / 177 페이지

← 이전다음 →